Wednesday, 15 November | 4:00 PM - 4:50 PM | Room 251BC
LEX Diagnostics have built upon core reagent systems provided by LGC Biosearch Technologies to develop an inhibitor tolerant reagent system. LEX believes point-of-care testing should provide high sensitivity tests that are easy to use and deliver clinically actionable results within a single visit to a health care provider. They have developed a rapid thermal cycling technology allowing gold standard sensitivity and specificity achievable through hydrolysis probe RT-PCR in a swab to result workflow. Learn how this technology eliminates the need for complex sample preparation and can efficiently amplify at groundbreaking speeds towards the realization of 5-minute PCR diagnostics.
Hear about:
Decentralized testing for faster prognosis and treatment
Developing reagent systems for extraction-free RT-PCR
Assay design for rapid amplification by thermal cycling
Developing a platform technology for a future assay menu
Add to calendar
Andrew Anyakwo
Head of Reagent Development, LEX Diagnostics
Andrew is the Head of Reagent Development at LEX Diagnostics. A clinical microbiologist by training with experience in working through the challenges posed by rapid molecular diagnostics. Andrew’s current drive is aiming high – for small-scale, affordable PCR testing that delivers reliable results in record time.
Be the first to hear about innovation in the molecular diagnostics industry by stopping by booth #925 and #1024. While on-booth, you can speak with fellow experts or participate in one of our Tech Talks. These 5-minute talks will dive into specific technical discussions ranging from assay development and commercialisation to best practices in NGS assay implementation and use of reference materials for quality control.
Thursday, 11/16, 4:00pm
Friday, 11/17, 9:30am
Friday, 11/17, 3:00pm
Saturday, 11/18, 9:30am
Improving assay performance with oligo modifications
Quality considerations for enzymes for molecular diagnostic assay development
Benefits of partnering with oligo applications experts early in the assay development process
POC diagnostic testing and unique requirements - Sample input to answer output
Thursday, 11/16, 4:30pm
Friday, 11/17, 9:45am
Friday, 11/17, 3:15pm
Reference Materials for the Analytical Validation and Development of Tumor Informed MRD Assays with David Merriam, Ph.D.
Purpose Built Reference Materials for Methylated cfDNA with Andrew Anfora, Ph.D.
Benchmarking HRD Assays with Reference Materials with David Merriam, Ph.D.
LGC Clinical Diagnostics are global leaders in clinical genomic assay implementation and routine quality control. Our portfolio of Seraseq® somatic cancer products enables the promise of clinical genomics with the design and manufacture of patient-like reference materials for use in the development, validation, and implementation of molecular next-generation sequencing (NGS) assays that support clinical evaluation and management of cancer diseases. These clinically relevant reference materials cover the functional areas of:
o Solid Tumor Profiling
o Liquid Biopsy
o Hematological Malignancy
o Tumor Mutational Burden
Many of the choices you make during the R&D phase can have a substantial impact on how successful you are in taking your molecular diagnostic assay to market. We share with you 6 tips for commercialisation.